Artificial cornea nearing clinical trial stage

Article

An artificial cornea based on a commercially available polymer, may be ready for clinical testing early in 2008.

An artificial cornea based on a commercially available polymer, may be ready for clinical testing early in 2008.

The cornea, developed by members of the European Union-funded CORNEA project, is made from a polymer that does not absorb water and does not allow cells to grow on it. After shaping the polymer, the researchers selectively coated the implants by laying masks on them and then applying a protein to the edge of the cornea, which the cells of the natural cornea can latch on to. This process allows the implant to connect firmly while keeping the centre of the cornea free of cells, thereby not impairing the patient's vision. The optical front part of the artificial cornea is coated with a hydrophilic polymer to keep it constantly moistened with tear fluid.

The first implants have already undergone successful animal testing and the researchers hope to begin human trials in 2008.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.